Evidence map›Paper›PMID 39488563›Full record

ArticleScientific reports2024

Development and validation of a nomogram for predicting overall survival of head and neck adenoid cystic carcinoma.

Yuhui Pan, Libin Zhang, Siqi Xu, Ying Li, Zongwei Huang, Chao Li, Sunqin Cai, Zihan Chen, Jinghua Lai, Jun Lu and 1 more

Abstract readValidation Study
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Observational
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Yuhui PanClinical Oncology School of Fujian Medical University, Fujian Cancer Hospital (Fujian Branch of Fudan University Shanghai Cancer Center), Fuzhou, Fujian, China.
Libin ZhangMedical Record Room, Fujian Cancer Hospital & Fujian Medical University Cancer Hospital, Fuzhou, Fujian, China.
Siqi XuClinical Oncology School of Fujian Medical University, Fujian Cancer Hospital (Fujian Branch of Fudan University Shanghai Cancer Center), Fuzhou, Fujian, China.
Ying LiClinical Oncology School of Fujian Medical University, Fujian Cancer Hospital (Fujian Branch of Fudan University Shanghai Cancer Center), Fuzhou, Fujian, China.
Zongwei HuangClinical Oncology School of Fujian Medical University, Fujian Cancer Hospital (Fujian Branch of Fudan University Shanghai Cancer Center), Fuzhou, Fujian, China.
Chao LiDepartment of Oncology, Second Hospital of Sanming City, Sanming, Fujian, China.
Sunqin CaiClinical Oncology School of Fujian Medical University, Fujian Cancer Hospital (Fujian Branch of Fudan University Shanghai Cancer Center), Fuzhou, Fujian, China.
Zihan ChenClinical Oncology School of Fujian Medical University, Fujian Cancer Hospital (Fujian Branch of Fudan University Shanghai Cancer Center), Fuzhou, Fujian, China.
Jinghua LaiClinical Oncology School of Fujian Medical University, Fujian Cancer Hospital (Fujian Branch of Fudan University Shanghai Cancer Center), Fuzhou, Fujian, China.
Jun LuClinical Oncology School of Fujian Medical University, Fujian Cancer Hospital (Fujian Branch of Fudan University Shanghai Cancer Center), Fuzhou, Fujian, China. lujvip@126.com.
Sufang QiuClinical Oncology School of Fujian Medical University, Fujian Cancer Hospital (Fujian Branch of Fudan University Shanghai Cancer Center), Fuzhou, Fujian, China. sufangqiu@fjmu.edu.cn.

Funding

Fujian Clinical Research Center for Radiation and Therapy of Digestive, Respiratory and Genitourinary Malignancies; National Natural Science Foundation of China 82072986Fujian Provincial Clinical Research Center for Cancer Radiotherapy and Immunotherapy 2020Y2012High-level Talent Training Program of Fujian Cancer Hospital 2022YNG07Innovative Medicine Subject of Fujian Provincial Health Commission, China 2021CXA029Joint Funds for the Innovation of Science and Technology, Fujian province 2021Y9196Major Research Projects for Young and Middle-aged Researchers of Fujian Provincial Health Commission 2021ZQNZD010Natural Science Foundation of Fujian province 2023J01121763Science and Technology Pilot Program of Fujian Province, China 2021Y0053The grants of Science and Technology Program of Fujian Province, China 2018Y2003The National Clinical Key Specialty Construction Program 2021Wu Jieping Medical Foundation 320.6750.2021-01-27
6 · The paper itself

Abstract

This study aimed to develop and validate a nomogram using clinical variables to guide personalized treatment strategies for adenoid cystic carcinoma of the head and neck (ACCHN). Data from 1069 patients with ACCHN diagnosed between 2004 and 2015 in the Surveillance, Epidemiology, and End Results (SEER) database were used to construct the nomogram. External validation was performed using an independent cohort of 70 patients from Fujian Cancer Hospital. Multivariate Cox regression analysis was conducted using IBM SPSS version 26.0 and R Software version 4.2.3. The concordance index (C-index) and receiver operating characteristic (ROC) curves were used to assess the predictive accuracy of the nomogram. Age, tumor site, surgery, N stage, M stage, and TNM stage were identified as independent prognostic factors through univariate and multivariate Cox analyses. The nomogram demonstrated superior predictive performance compared to the TNM staging system, effectively stratifying patients into high-risk and low-risk groups. This nomogram offers a valuable tool for predicting overall survival in patients with ACCHN and tailoring individualized treatment approaches.

Indexed as

Carcinoma, Adenoid CysticHead and Neck NeoplasmsNomogramsAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedNeoplasm StagingPrognosisProportional Hazards ModelsROC CurveSEER ProgramYoung AdultAdenoid cystic carcinomaHead and neck cancerNomogramOverall survivalPrognostic factors

Identifiers

PMID39488563
PMCPMC11531573

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.